Active Ingredient History
Serlopitant (INN, codenamed VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication. Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch) Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcoholism (Phase 2)
Burns (Phase 2)
Cough (Phase 2)
Dermatitis, Atopic (Phase 3)
Epidermolysis Bullosa (Phase 2)
Prurigo (Phase 3)
Pruritus (Phase 3)
Psoriasis (Phase 3)
Urinary Bladder, Overactive (Phase 2)
Urinary Incontinence (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue